Please assess the completion status of the following clinical trial:

Trial Title: Cardiac Uptake of 18F Florbetapir in Patients Undergoing Chemotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients aged \> 18 years are eligible.~2. Patient must provide informed consent to participate in the study protocol.~3. All patients must have clinical diagnosis of cardiac AL amyloidosis (typical echocardiographic or cardiac MRI findings, NT-ProBNP levels above 332 pg/mL, cardiac or extra cardiac histological evidence of light chain amyloidosis).~4. Planned plasma cell-directed chemotherapy.~5. A negative pregnancy test will be required for all women of child bearing potential, breast feeding is not permitted.~6. Patients must be able to undergo PET-CT imaging~7. Patients must be able to complete 6-minute walk test~Exclusion Criteria:~1. Severe claustrophobia~2. Pregnancy~3. Allergy to F-18 florbetapir

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with AL cardiac amyloid (Type: EXPERIMENTAL): Patients enrolled will be patients \> 18 years of age with a clinical diagnosis of cardiac AL amyloidosis (typical echocardiographic or MRI findings, NT-ProBNP levels above 332 pg/mL, cardiac or extra cardiac histological evidence of light chain amyloidosis) with plans to undergo plasma cell directed chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).